The impact of SGLT2-inhibitor on SLE outcomes SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors. https://t.co/hyyMVQg3xV https://t.co/fLxh0vlTze

• The impact of SGLT2-inhibitor on SLE outcomes | RheumNow

Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN

• Are Rheumatologists doing Enough for Cervical Cancer? | RheumNow

Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/91PtvQfoIr https://t.co/ZjYCVP5lqG

• Efficacy and safety of avacopan in patients with ANCA-associated vasculitis rec…

Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR 1.33) RCTs; highest in ACPA+ smokers (SMR 2.80 & 2.14); Cancer main cause. SMR incr 34% & 13% for ea 1 pt incr in DAS https://t.co/2DdHMGIlOk https://t.co/7bnCOzB8vd

• Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMP…

Infections During Treatment of GPA with Rituximab Dr. Richard Conway (Dublin, Ireland) discusses abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/eKi3KExEnk https://t.co/b9G9w5e9tc

• Infections During Treatment of GPA with Rituximab | RheumNow

Watch and Weigh In: Upadacitinib for Pain: Is That Real? Dr. David Liew reports on abstract 0429 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AbD9UpXQfY https://t.co/iRgUnNInuD

• Upadacitinib for Pain: Is That Real? | RheumNow

Computer Vision: Is It Ready for RA Assessment? Dr. David Liew reports on abstract 0402 and 1293 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/4rQDjFXjH2 https://t.co/8FM40kh3bw

• Computer Vision: Is It Ready for RA Assessment? | RheumNow

Hemophagocytic Lymphohistiocytosis in Still's Disease Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm

• Hemophagocytic Lymphohistiocytosis in Still's Disease | RheumNow

Watch: Deep Neural Networks and Radiographic Progression in AxSpA Dr. Antoni Chan discusses abstracts 1389 and 1398 presented at the 2023 ACR Convergence in San Diego, CA. https://t.co/F9hpNvmvVc https://t.co/xR0uW1CkUw

• Deep Neural Networks and Radiographic Progression in AxSpA | RheumNow

The impact of SGLT2-inhibitor on SLE outcomes SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors. https://t.co/BjjerQhsrR https://t.co/vpzSaAIOjU

• The impact of SGLT2-inhibitor on SLE outcomes | RheumNow

Are Rheumatologists doing Enough for Cervical Cancer? Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients. https://t.co/FKaLSiBHV6 https://t.co/zR46JU5mlR

• Are Rheumatologists doing Enough for Cervical Cancer? | RheumNow